aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LIFE
CUSIP53217V10
Phone858-731-8389
Debt
Debt-to-Equity Ratio0.24
Current Ratio6.90
Quick Ratio6.90
Price-To-Earnings
Trailing P/E Ratio-0.48
Forward P/E Ratio-0.70
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.16 per share
Price / Book0.41
Profitability
EPS (Most Recent Fiscal Year)($1.87)
Net Income$-48,200,000.00
Net MarginsN/A
Return on Equity-78.72%
Return on Assets-56.17%
Miscellaneous
Employees65
Outstanding Shares29,830,000
Market Cap$26.66
aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) issued its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.01. View aTyr Pharma's Earnings History.
When is aTyr Pharma's next earnings date?
What price target have analysts set for LIFE?
4 Wall Street analysts have issued 12-month target prices for aTyr Pharma's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate aTyr Pharma's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 293.3% from the stock's current price. View Analyst Ratings for aTyr Pharma.
What is the consensus analysts' recommendation for aTyr Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Brainstorm Cell Therapeutics (BCLI), Champions Oncology (CSBR), Applied Genetic Technologies (AGTC), Entera Bio (ENTX), Genocea Biosciences (GNCA), Curis (CRIS), BioCardia (BCDA), Aevi Genomic Medicine (GNMX), TRACON Pharmaceuticals (TCON), Arsanis (ASNS), Proteon Therapeutics (PRTO), BIONDVAX PHARMA/S (BVXV), CytRx (CYTR), Microbot Medical (MBOT) and Oncobiologics (ONS).
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 46)
- Dr. Paul R. Schimmel, Founder & Director (Age 77)
- Dr. David J. King, Chief Scientific Officer (Age 59)
- Dr. John D. Mendlein, Strategic Advisor & Director (Age 58)
- Dr. Sanuj K. Ravindran, Bus. Advisor (Age 46)
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Has aTyr Pharma been receiving favorable news coverage?
Media coverage about LIFE stock has been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. aTyr Pharma earned a coverage optimism score of 0.10 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of aTyr Pharma?
Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of LIFE stock can currently be purchased for approximately $0.89.
How big of a company is aTyr Pharma?
aTyr Pharma has a market capitalization of $26.66 million. The biotechnology company earns $-48,200,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. aTyr Pharma employs 65 workers across the globe.
How can I contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]
MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
